Progressive multifocal leukoencephalopathy (PML) associated with polyomavirus JC (JCV) infection has been reported to be usually fatal in allogeneic hematopoietic SCT (HSCT) recipients. We present the case of a 19-year-old HSCT patient diagnosed with JCV-associated PML after prolonged immunosuppression for severe GVHD. No short-term neurological improvement was observed after antiviral treatment and discontinuation of immunosuppressive therapy. Donor-derived JCV Ag-specific CTLs were generated in vitro after stimulation with 15-mer peptides derived from VP1 and large T viral proteins. After adoptive CTL infusion, virus-specific cytotoxic cells were shown in the peripheral blood, JCV-DNA was cleared in the cerebrospinal fluid and the patient showed remarkable improvement. Adoptive T-lymphocyte therapy with JCVspecific CTLs was feasible and had no side effects. This case suggests that adoptive transfer of JCV-targeted CTLs may contribute to restore JCV-specific immune competence and control PML in transplanted patients.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by polyomavirus JC (JCV), occurring in immunocompromized hosts.
1,2 Current understanding of the disease mostly results from HIV-positive patients developing AIDS. 1 The PML-attributable 1-year mortality rate is greater than 50% in HIV-AIDS patients, with 80% of survivors showing severe neurological impairment. 3 PML is also observed in recipients of either solid organ or hematopoietic SCT (HSCT) and, more recently, in patients undergoing lymphocyte-targeted drug treatment for autoimmune diseases. [4] [5] [6] The prognosis in transplanted patients is less defined, but the case fatality rate seems to be even higher than in HIV-AIDS patients. 7 Several antiviral compounds, including cidofovir, have polyomavirus-specific activity in vitro, although none has proved clinically effective against JCV in HIV-positive patients. 8 Despite the lack of specific treatment, the immune reconstitution induced by highly active antiretroviral therapy (HAART) significantly improved survival in AIDS patients. 9 In this population, the appearance of JCV-specific CD8 þ CTLs plays a major role in controlling PML and is associated with improved outcome. [10] [11] [12] In HSCT recipients, there is a rationale for enhancing/rebuilding JCV-specific immunity through adoptive cell therapy, as there is sound evidence that the transfer of donor-derived, Ag-specific T-lymphocytes can restore protective immunity and control other viral infections. [13] [14] [15] [16] We report the case of a patient presenting with JCVassociated PML 5 years after HSCT, who improved after immunosuppression discontinuation and combined treatment, including donor-derived JCV-specific CTL.
Case report
A 14-year-old male patient was allografted from an HLAidentical sibling for very-high-risk ALL. Following engraftment, he experienced grade III acute GVHD, which progressed into extensive chronic GVHD, persisting for years. Multiple lines of immunosuppression included combinations of steroids, CYA, mycophenolate mofetil, extracorporeal photochemotherapy, rituximab, CY and MTX. At 5 years after transplantation, all immunosuppressive drugs were tapered and discontinued when lowdose imatinib and budesonide alone were able to control GVHD for 6 months. At that time, at 19 years of age, the patient complained of progressive, severe visual impairment, causing inability to read, write and perform daily activities. Initially diagnosed with bilateral cataracts, after surgical treatment he showed no improvement. After a transient upper left limb paresis, associated with panic attacks, neurological examination revealed severe slowing, unstable gait, postural and intentional limb tremor with a spastic component, motor weakness, mild rigor nucalis, sensitive and motor aphasia, apraxia, agnosia, memory loss, mental dullness and visual field deficiencies. Magnetic resonance imaging (MRI) showed bilateral, multiple occipito-temporo-parietal subcortical lesions and hyperintense signal in the right thalamus ( Figure 1a) . 17 Electroencephalogram showed diffuse electrical slowing, mostly involving frontal and temporo-occipital areas of the right hemisphere, without focal epileptic activity. The neuropsychological assessment documented severe global impairment of cognitive functions (Mini-Mental State corrected for age and school level, 14.6 of 23.8) (Figure 2) . 18 Blood counts and biochemistry were normal, except for lymphocyte counts, which were low (CD4
/L). Pathogen-specific blood serologies and viral PCR analyses, including JCV search, 19 were negative. Cerebrospinal fluid (CSF) analyses were normal, except for JCV-DNA (8645 copies per ml). The JCV positivity, consistent with clinical and radiological findings, allowed a diagnosis of JCV-associated PML. 20 Ongoing imatinib and budesonide were discontinued and treatment with a serotonin reuptake inhibitor (citalopram, 20 mg daily) and cidofovir (5 mg/kg twice in the first week, and then once every other week) was administered. Concomitantly, donor-derived JCV-specific CTL preparation was started. At 44 days after the diagnosis of PML, the patient reported minimal clinical improvement, JCV-DNA persisted in the CSF (800 copies per ml) ( Figure 2 ) and the MRI showed enlargement of the known lesions and additional lesions (Figure 1b) . At that time, cell therapy was considered in order to accelerate virus-specific immune reconstitution.
Methods

Generation of JCV-specific T-lymphocyte lines
Ag-specific T-lymphocyte lines were generated as recently described in the polyomavirus BK setting. 21 Briefly, 2 Â 10 6 donor PBMCs were pulsed with 15-mer peptide pools, spanning the entire JCV-VP1 and large T (LT) proteins (5 ng/mL concentration of each mix; Eurogentec, Seraing Belgium) 22 in 1 ml volume of X-VIVO 20 medium containing 10% autologous or human AB serum. On day þ 12, cultured cells were recovered, counted and re-plated at 2 Â 10 5 per well in 24-well plates, pre-incubated overnight with 1 Â 10 6 autologous irradiated stimulator PBMC, pulsed with 50 ng/mL JCV-VP1 and LT peptide mixes. On days þ 15, þ 19 and þ 22, IL-2 (20 U/mL) was added to the culture. On day þ 26, T-cell lines were harvested and examined for immunophenotype, alloreactivity and JCV specificity in a proliferation assay by 3 H-thymidine incorporation, 23 in a cytotoxicity test by standard 51 Crrelease assay, 21 and capacity to produce IFNg in an enzyme-linked immunospot assay. 21 Assays for Ag-specific responses To evaluate JCV-specific responses, patient PBMCs, obtained after density gradient stratification, were cultured for 8 days in the presence of 500 ng/mL JCV-VP1 and LT peptides, and then tested for specific cytotoxicity by means of a standard 51 Cr-release assay against a panel of targets, including autologous PHA blasts pulsed with 2 mg/mL of VP-1 and LT peptide mix or with 2 mg/mL of control peptide. 21 JCV-specific antibodies were tested using viruslike particles, as described previously. 24 Cytotoxicity was selected as an adequate readout to evaluate JCV-specific response considering that cytotoxic T cells have been shown crucial for the control of polyomavirus-related disease in immunocompromised patients. 
Results
Biological characterization of JCV-targeted T-lymphocyte lines JCV-specific T-cell lines were successfully generated ex vivo from the HSCT donor. Flow-cytometry analyses showed that 37% of cells were CD8 þ and 43% CD4 þ , whereas 10% were CD3 þ /TCRgd þ and 9% natural killer (CD56 þ / CD3 À ). CTL lines were specific for JCV, as they proliferated and produced IFNg in response to JCV-VP1 and LT peptide mix and exerted virus-specific cytotoxicity, showing specific lysis toward JCV Ag-pulsed targets (effector to target ratio of 5:1 after subtracting control lysis: PHA-VP1, 24±2%; PHA-LT, 0%) ( Table 1 ). The absence of proliferation in response to patient PBMC or lysis of patient PHA blasts indicated that the cell line was devoid of aspecific reactivity against autologous targets.
CTL infusion
In compliance with Institutional Guidelines and after obtaining written informed consent from the patient and his parents, 0.5 Â 10 6 and 1 Â 10 6 JCV-specific T cells per kg were infused at 54 and 121 days after PML diagnosis, respectively ( Figure 2) . No GVHD flare or other adverse events were recorded. Clinical assessment for PML was performed 5 weeks after the second infusion, which corresponded to day þ 156 after PML diagnosis. Neither clinical nor biochemical/instrumental assessment was planned between the two infusions as we tried to preserve the patient's quality of life given his poor prognosis.
Immune responses to JCV Lymphocytes collected from the patient before T-lymphocyte infusion showed no JCV-specific cytotoxicity after 8-day stimulation with JCV Ags. Serial evaluations after CTL infusions revealed the emergence of a measurable lytic activity toward JCV-VP1-pulsed targets, whereas JCV-LTdirected lysis remained mainly undetectable (Figure 2) . The VP1-directed cytotoxicity was mediated by both CD8 þ and CD4 þ lymphocyte subsets (see notes to Table 1 ). JCV-specific antibodies in the CSF showed a high OD 492 nm activity of 1.165 compared with 164.12 in the serum, indicating a high intrathecal JCV-specific Ab production (JCV-specific IgG index 19.5) as a sign of significant JCV-specific humoral immune reconstitution.
Clinical evaluation
On day þ 156, JCV-DNA in CSF was undetectable, lymphocyte counts were increased (CD4
/L) and a remarkable neurological improvement, never detected in the previous evaluations, was reported. The patient was able to walk unattended, his gross motor function recovered despite postural tremor, muscle weakness, mostly on the left side, and impairment in the fine motor function. He was well oriented and able to follow orders correctly, although his speech was slightly slow and his reading still impaired. Neuropsychological evaluation improved markedly (Mini-Mental State 27.59) 18 ( Figure 2 ) despite residual mild impairment in visualspatial functions, persistent constructional apraxia and deficit in denomination on visual stimulus. MRI was performed 20 days after the second CTL infusion. No edema was detected, the hyper-intense lesions were reduced and diffuse cerebral atrophy was evident (Figure 1 ). The electroencephalogram pattern was consistently improved and showed mild global slowing, with a temporo-parietooccipital focus, without epileptical discharges. Cidofovir administration was discontinued 6 months after PML diagnosis. Clinical re-assessment for PML was repeated every 3 months; the patient reported progressive mild neurological improvement, that is, normal speech, ability to work, read and even drive. At 26 months after PML diagnosis, the patient shows neither further signs of clinical deterioration nor evidence of GVHD.
Discussion
We report on the successful in vitro generation of a JCVspecific CTL line and its clinical use in an HSCT recipient with JCV-related PML, which possibly contributed to specific immune reconstitution and, eventually, to clinical improvement. The method for generating virus-specific CTLs was based on stimulation with a mix of 15-mer peptides, spanning the whole JCV VP1 and LT proteins. 12, 21, 22 In healthy individuals and patients with PML, Koralnik et al.
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described CTL responses in vitro to VP1p 36 and VP1p 100 epitopes, which were restricted to individuals carrying the allele *0201 at the HLA-A locus. The use of overlapping peptide pools has the potential advantage of extending cell therapy to all individuals, regardless of HLA typing. Moreover, the CTL line generated with overlapping peptide pools included both CD8 þ and CD4 þ T cells and was able to exert CD4 and CD8 T-cell mediated cytotoxicity in the patient, most likely as a result of Ag presentation in the context of both HLA class I and II molecules. In addition to the role possibly played by CD8 þ lymphocytes, 10-12 the presence of CD4 þ T-lymphocytes may also be relevant to the final PML outcome, as this lymphocyte subset was shown to have a crucial role not only in providing helper functions, but also in exerting direct control in vivo of viral and tumor replication. [25] [26] [27] The observation that no GVHD flare occurred in our patient following donor JCV-specific CTL infusion, despite his previous severe chronic GVHD, confirms that the selection of virus-specific populations, through repeated rounds of antigenic-specific stimulation, efficiently depletes alloreactive T-lymphocytes. 15 The prognosis of PML is dismal after allogenic HSCT; in the last published review, it was reported to be fatal in five out of six HSCT patients and was associated with severe neurological sequelae in the only survivor. 7 In our patient, PML occurred 5 years after transplantation, after prolonged multidrug immune-suppressive therapy for chronic GVHD, which included rituximab and mycophenolate mofetil, both reported to be sporadically associated with PML (www.fda.gov/medwatch/safety). A treatment strategy consisting of discontinuation of immune-suppressive therapy, administration of cidofovir and serotonin-reuptake inhibitor, as well as of JCV-specific T-lymphocyte infusion, was able to produce a favorable clinical outcome. As a combined treatment approach was adopted, the contribution of each therapeutic element is difficult to assess in this patient. The role of cidofovir cannot be excluded but seems unlikely, as its lack of efficacy has been widely reported in HIV-positive patients with PML. 9, 28 Likewise, serotonin-reuptake inhibitors, which can inhibit receptor-mediated JCV endocytosis in glial cells, 29 have never been shown to be effective in vivo in PML patients. It is reasonable to hypothesize that discontinuation of any treatment with immune-suppressive effects may contribute to immune reconstitution, as shown in recently published reports. However, imatinib does not seem to be among the most detrimental agents active on immune cells, as autologous bcr/abl-specific T-cell immunity may emerge and persist in patients with chronic myeloid leukemia treated with this tyrosine-kinase inhibitor. 30 Therefore, we believe that, in our patient, restoration of JCV-specific immunity was promoted by immunosuppression discontinuation and enhanced by the adoptive infusion of virus-specific cell lines. Indeed, no JCV-specific cytotoxicity was detectable after discontinuation of immune-suppressive therapy and before CTL infusion, a finding that would have predicted an unfavorable outcome, given JCV persistence in CSF. 10, 11 The unexpected and remarkable clinical improvement, persisting 26 months after PML diagnosis, was actually detected shortly after CTL infusion, concomitantly with the appearance of circulating JCVspecific cytotoxic activity, JCV-DNA clearance from CSF and detection of intrathecal JCV-specific antibodies. Even if, for technical reasons, it was not possible to dissect transferred vs endogenous T-cell reconstitution, the contribution of infused T cells to endogenous specific immune reconstitution is at the basis of T-cell therapy and has proved to be effective in various settings.
Of note, the appearance of specific CTLs, after adoptive cell therapy, caused no further brain parenchymal damage. This finding is highly relevant, as the recovery of overall immunity can cause an immune reconstitution-related inflammatory syndrome, which is a potentially fatal complication of PML in HIV-AIDS patients receiving HAART. 31 The same pattern has also been observed after discontinuation of natalizumab treatment in patients with multiple sclerosis developing PML. [32] [33] In our patient, the recovery of specific immunity, and, in particular, of JCVspecific cytotoxic T-cell populations, contributed to viral control without inducing an immune reconstitution-related syndrome. This may be the result of JCV-specific CTL infusion, as the presence of mature effector cells activated in vitro may have enhanced endogenous virus-specific immunity without the activation of unspecific effector cells, likely responsible for reconstitution-related inflammatory reaction.
In summary, we show that adoptive T-lymphocyte therapy with JCV-specific CTL was feasible and presented no adverse side effects in HSCT recipients experiencing 
